Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,312 | 0,329 | 21:22 | |
0,312 | 0,329 | 21:22 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Carmat is running out of cash | 3 | MassDevice | ||
20.06. | In a Context of Critical Financial Situation, CARMAT Launches a Donation Campaign Open to All to Contribute to Its Funding and Continuation of Its Activities | 275 | Business Wire | Risk of insolvency as early as end of June 2025
Launch of a donation campaign open to all via the onparticipe.fr online platform
To listen to CARMAT CEO's message,
click here
Regulatory... ► Artikel lesen | |
CARMAT Aktie jetzt für 0€ handeln | |||||
20.06. | CARMAT Announces Being in a Critical Financial Situation and at Risk of Insolvency as of End-June 2025 | 326 | Business Wire | Immediate need to secure approximately €3.5 million to avoid insolvency at the end of June 2025
Total funding needs of around €35 million over the next 12 months
Ongoing active exploration... ► Artikel lesen | |
02.06. | CARMAT Announces the First Commercial Implants of Its Aeson Artificial Heart Outside the European Union | 300 | Business Wire | Two implants have recently been performed in Israel
Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide... ► Artikel lesen | |
12.05. | CARMAT Completes Enrolment in the EFICAS Clinical Study and Receives Approval From French Authorities for 21 Additional Aeson Implants, While Awaiting Potential Reimbursement of the Device in France | 262 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
30.04. | CARMAT: Availability of the 2024 Universal Registration Document | 348 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
29.04. | CARMAT Announces Its 2024 Annual Results | 425 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
14.04. | CARMAT Receives FDA Conditional Approval to Initiate the Second Cohort of the EFS Study in the United States | 279 | Business Wire | Recruitment of the second cohort expected to begin in H2 2025
Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming... ► Artikel lesen | |
09.04. | CARMAT Delivers Q1 2025 Results in Line With Its Objectives | 273 | Business Wire | Quarterly sales of €2.4m multiplied by 2.4 vs Q1 2024
EFICAS clinical trial recruitment 94% complete
2 scientific publications a strong driver of Aeson® adoption
Final stage... ► Artikel lesen | |
03.04. | CARMAT - Publication in the JACC(1): Heart Failure of the Initial Clinical Experience with Aeson Total Artificial Heart in Cardiogenic Shock Patients Initially Placed on Extracorporeal Life Support | 310 | Business Wire | The retrospective analysis on 10 patients shows a 90% survival rate at 6 months, suggesting Aeson® as a therapeutic solution for these patients at risk of death in the short term.
Regulatory News:
CARMAT... ► Artikel lesen | |
31.03. | CARMAT to Provide a Business Update and Host a Videoconference on April 9, 2025 | 299 | Business Wire | Please register to the videoconference by clicking on one of the following links: Videoconference in French at 6:00 pm CEST -
Videoconference in English at 8:00 pm CEST
Regulatory News:
CARMAT... ► Artikel lesen | |
27.03. | CARMAT announces the implementation of a flexible equity financing line with IRIS Capital Investment | 402 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
17.02. | CARMAT: Aeson total artificial heart highlighted as a very promising solution for heart failure patients with pulmonary hypertension in The Journal of Heart and Lung Transplantation | 526 | Business Wire | Up to 25% of advanced heart failure patients suffer from pulmonary hypertension
Aeson® could potentially become a standard treatment for these thousands of patients, both as a bridge-to-transplant... ► Artikel lesen | |
10.02. | CARMAT Achieves the Milestone of 100 Implants of Its Aeson Total Artificial Heart | 372 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
31.01. | CARMAT Raises a Total of €9.7 Million | 707 | Business Wire | Regulatory News:
NOT FOR DIRECT OR INDIRECT DISTRIBUTION IN THE UNITED STATES OF AMERICA, SOUTH AFRICA, CANADA, AUSTRALIA OR JAPAN
CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), designer and developer... ► Artikel lesen | |
30.01. | CARMAT Launches a €10 Million Global Offering With €7 Million in Subscription Commitments | 678 | Business Wire | Global Offering composed of a reserved offering for qualified investors and a public offering for retail investors via the PrimaryBid platform
Issue price for new shares set at 0.77 euro... ► Artikel lesen | |
29.01. | CARMAT: 2025 Financial Calendar | 422 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
13.01. | CARMAT Announces Its Participation in Several Scientific and Investor Conferences During the 1st Half of 2025 | 423 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
08.01. | CARMAT Delivers a Solid FY 2024 with 42 Implants of Its Aeson Artificial Heart and Anticipates Continued Strong Momentum in 2025 | 412 | Business Wire | Over 90 patients have received the Aeson® artificial heart since the first implant in 2013, including 42 in 2024.
2024 Sales of €7 million (a 2.5-fold increase vs 2023).
Cash burn... ► Artikel lesen | |
23.12.24 | CARMAT optimizes its financial structure by buying-back, for a symbolic sum of one euro, 2 million shares from Matra-Défense (Airbus group) which will be allocated to the repayment of its financial debt | 587 | Business Wire | Buy-back by CARMAT of 2 million shares from Airbus for a symbolic sum of 1 euro. The shares so bought-back will be allocated to the repayment of the Company's financial debt, via their... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
FRESENIUS | 42,590 | +0,95 % | EQS-PVR: Fresenius SE & Co. KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
20.06.2025 /... ► Artikel lesen | |
FRESENIUS MEDICAL CARE | 48,300 | +0,52 % | BERENBERG stuft FMC FRESENIUS MEDICAL CARE AG auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Fresenius Medical Care (FMC) von 55 auf 60 Euro angehoben und die Einstufung auf "Buy" belassen. Analystin Victoria Lambert... ► Artikel lesen | |
SIEMENS HEALTHINEERS | 46,900 | +0,13 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
CARL ZEISS MEDITEC | 57,00 | +1,06 % | Aktienmarkt: Aktie von Carl Zeiss Meditec kann sich nicht behaupten (56,30 €) | Im deutschen Wertpapierhandel liegt die Carl Zeiss Meditec-Aktie gegenwärtig im Minus. Das Wertpapier kostete zuletzt 56,30 Euro. Ein Wertverlust in Höhe von 1,75 Euro müssen derzeit die Aktionäre von... ► Artikel lesen | |
ECKERT & ZIEGLER | 67,85 | +2,03 % | Leichte Zugewinne bei der Eckert&Ziegler-Aktie (65,60 €) | Die Eckert&Ziegler-Aktie notiert heute etwas fester. Das Wertpapier kostete zuletzt 65,60 Euro. Eine Verteuerung in Höhe von 1,75 Euro erfreut derzeit die Aktionäre von Eckert&Ziegler. Zur Stunde kostet... ► Artikel lesen | |
DRAEGERWERK | 67,10 | +0,15 % | Dräger-Aktie legt um 0,15 Prozent zu (67,10 €) | Im deutschen Wertpapierhandel liegt das Wertpapier von Dräger zur Stunde im Plus. Der jüngste Kurs betrug 67,10 Euro. Das Wertpapier von Dräger verzeichnet aktuell ein Kursplus von 0,15 Prozent. Es... ► Artikel lesen | |
MEDTRONIC | 73,67 | 0,00 % | Dividendenbekanntmachungen (27.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AGC INC JP3112000009 105 JPY 0,6216 EUR ALERUS FINANCIAL CORPORATION US01446U1034 0,21 USD 0,1795 EUR ALICO INC US0162301040 0... ► Artikel lesen | |
INTUITIVE SURGICAL | 459,00 | +0,57 % | Intuitive Surgical Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
UNITEDHEALTH | 262,65 | +1,59 % | Dividendenbekanntmachungen (24.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) COMPAGNIE DE L ODET SA FR0000062234 - 4,4 EUR DOM DEVELOPMENT SA PLDMDVL00012 7 PLN 1,6374 EUR ELBIT SYSTEMS LTD IL0010811243 0... ► Artikel lesen | |
GERRESHEIMER | 48,080 | +1,26 % | Deutsche Pfandbriefbank, Gerresheimer, Hugo Boss, Renk, Rheinmetall, Symrise - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
TELADOC HEALTH | 7,103 | +3,21 % | Aktien-Trading 4 Dummies - 3 Aktien. 2 Experten. 0 Langeweile (Hims & Hers, Teladoc & XTI Aerospace) | ||
THERMO FISHER | 348,05 | -1,18 % | Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply | Scope of Agreement with Cambrex to Provide Ondansetron HCL Drug Substance Under FDA Approved Drug Master File Scope Of Agreement With Thermo Fisher to Provide Manufacturing Services Including Demonstration... ► Artikel lesen | |
STRATEC | 26,800 | -0,56 % | MARKT/Stratec und Nagarro profitieren von Delisting der Compugroup | DJ MARKT/Stratec und Nagarro profitieren von Delisting der Compugroup
Das angekündigte Delisting der Compugroup bringt bei Vollzug Nagarro in den TecDAX zurück und Stratec in den SDAX. Compugroup... ► Artikel lesen | |
RHOEN-KLINIKUM | 11,900 | +1,71 % | 100.000 Operationen seit Einzug in den Neubau - RHÖN-KLINIKUM Campus Bad Neustadt zieht positive Bilanz | Bad Neustadt a.d. Saale (ots) - Hohe Operationszahlen spiegeln medizinische Kompetenz und strukturelle Stärke wider: Seit dem Einzug in den hochmodernen Neubau 2018/2019 hat der RHÖN-KLINIKUM Campus... ► Artikel lesen | |
HIMS & HERS HEALTH | 41,880 | +5,86 % | Kein Wegovy mehr: Novo Nordisk bricht Partnerschaft: Hims & Hers-Aktie fällt ins Bodenlose! | © Foto: Christian Schultz/dpaNovo Nordisk bricht mit Hims & Hers: Beide Aktien fallen drastisch, wobei der Telemedizinanbieter aus den USA den Kürzeren zieht.Tiefschlag für die Anteilsscheine von Hims... ► Artikel lesen |